Join the Alopecia group to help and get support from people like you.
Alopecia News
Related terms: Alopecia Areata, Balding, Baldness, Baldness, female pattern, Hair Loss, Hairloss, Hair Thinning, Loss of Hair
Childhood Obesity Tied to Pediatric Immune-Mediated Skin Diseases
TUESDAY, Aug. 27, 2024 – Early childhood obesity may increase the risk for pediatric immune-mediated skin diseases, according to a study published online Aug. 21 in the Journal of Investigative ...
Alopecia Tied to Higher Prevalence of Autoimmune, Psychiatric Comorbidities
TUESDAY, Aug. 6, 2024 – Patients with alopecia areata (AA) have a higher prevalence of autoimmune and psychiatric comorbidities at time of diagnosis as well as a higher risk for new-onset autoimmune...
FDA Approves Leqselvi for Severe Alopecia
FRIDAY, Aug. 2, 2024 – The U.S. Food and Drug Administration has approved Leqselvi (deuruxolitinib) tablets for the treatment of adults with severe alopecia areata. Leqselvi (8 mg) is a twice-daily...
FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
MUMBAI, India and PRINCETON, N.J., July 26, 2024 /PRNewswire/ – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its...
Microneedle Patch Might Restore Hair Growth After Alopecia
MONDAY, June 10, 2024 – Researchers have developed a novel way to promote hair growth in people who have the autoimmune disease alopecia areata. It's a skin patch that delivers immune-system...
Microneedle Patches Might Reverse a Form of Hair Loss
MONDAY, May 13, 2024 – Early research in mice suggests a new path forward to restoring hair growth in people affected by a form of alopecia. Alopecia areata is an autommune disorder that affects an ...
Kids With Common Skin Conditions Face Stigma, Bullying
WEDNESDAY, April 24, 2024 – Acne, psoriasis, eczema, vitiligo, alopecia: Any one of these common skin ailments can render a child vulnerable to stigma and bullying at school, new research confirms....
AAD: Continuous Improvements Seen Through 68 Weeks for Deuruxolitinib in Alopecia
TUESDAY, March 19, 2024 – For adults with alopecia areata, continuous improvements are seen through 68 weeks with deuruxolitinib, according to a study presented at the annual meeting of the American...
AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia
MONDAY, March 18, 2024 -- Continuous treatment with baricitinib in patients with severe alopecia areata demonstrates improvement in hair regrowth outcomes through 76 weeks of follow-up, according to ...
New Side Effects Reported for GLP-1 RA Weight-Loss Drugs
THURSDAY, Jan. 4, 2024 – In a quarterly report issued this week, the U.S. Food and Drug Administration said it is investigating cases of hair loss, aspiration, and suicidal ideation in people who...
FDA Looking Into New Risks With Popular Weight-Loss Drugs
THURSDAY, Jan. 4, 2024 – The U.S. Food and Drug Administration is investigating reports of additional dangers linked to several wildly popular weight-loss drugs. In a quarterly report issued this w...
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 – In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report. Conditions such as alopecia (hair loss), psoriasis,...
Autoimmune, Autoinflammatory Connective Tissue Disorders Increased After COVID-19
TUESDAY, Oct. 10, 2023 – COVID-19 is associated with an increased risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Oct. 6 in JAMA Network...
Study Looks at Treatment Patterns for Alopecia Areata
WEDNESDAY, Sept. 20, 2023 – For patients with alopecia areata (AA), corticosteroids are the most commonly used treatment, and by one year, 71.8 percent are receiving no treatment, according to a...
FDA Approves Litfulo (ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
NEW YORK--(BUSINESS WIRE) June 23, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Litfulo™ (ritlecitinib), a once-daily oral treatment, f...